杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2025/05/23 | 1,463 | 1,469 | 1,450 | 1,460 | -2 | -0.1% | 99,500 |
| 2025/05/22 | 1,456 | 1,468 | 1,446 | 1,462 | -7 | -0.5% | 89,300 |
| 2025/05/21 | 1,453 | 1,471 | 1,451 | 1,469 | +16 | +1.1% | 77,800 |
| 2025/05/20 | 1,477 | 1,481 | 1,453 | 1,453 | -13 | -0.9% | 130,600 |
| 2025/05/19 | 1,441 | 1,467 | 1,440 | 1,466 | +13 | +0.9% | 129,400 |
| 2025/05/16 | 1,445 | 1,455 | 1,433 | 1,453 | +12 | +0.8% | 79,900 |
| 2025/05/15 | 1,441 | 1,447 | 1,427 | 1,441 | -19 | -1.3% | 98,500 |
| 2025/05/14 | 1,460 | 1,471 | 1,437 | 1,460 | -16 | -1.1% | 120,300 |
| 2025/05/13 | 1,518 | 1,525 | 1,472 | 1,476 | +18 | +1.2% | 145,900 |
| 2025/05/12 | 1,488 | 1,495 | 1,458 | 1,458 | -30 | -2% | 125,000 |
| 2025/05/09 | 1,466 | 1,495 | 1,460 | 1,488 | +24 | +1.6% | 66,700 |
| 2025/05/08 | 1,478 | 1,481 | 1,454 | 1,464 | -6 | -0.4% | 73,400 |
| 2025/05/07 | 1,473 | 1,479 | 1,455 | 1,470 | -16 | -1.1% | 73,400 |
| 2025/05/02 | 1,471 | 1,492 | 1,471 | 1,486 | +11 | +0.7% | 78,800 |
| 2025/05/01 | 1,470 | 1,481 | 1,463 | 1,475 | +1 | +0.1% | 88,600 |
| 2025/04/30 | 1,482 | 1,485 | 1,472 | 1,474 | -8 | -0.5% | 104,400 |
| 2025/04/28 | 1,491 | 1,499 | 1,482 | 1,482 | +5 | +0.3% | 110,200 |
| 2025/04/25 | 1,503 | 1,505 | 1,477 | 1,477 | -18 | -1.2% | 140,700 |
| 2025/04/24 | 1,508 | 1,517 | 1,487 | 1,495 | -23 | -1.5% | 171,100 |
| 2025/04/23 | 1,488 | 1,553 | 1,481 | 1,518 | +42 | +2.8% | 653,200 |
| 2025/04/22 | 1,476 | 1,487 | 1,464 | 1,476 | ±0 | ±0% | 52,100 |
| 2025/04/21 | 1,464 | 1,476 | 1,462 | 1,476 | ±0 | ±0% | 40,300 |
| 2025/04/18 | 1,465 | 1,479 | 1,453 | 1,476 | +28 | +1.9% | 48,500 |
| 2025/04/17 | 1,446 | 1,454 | 1,431 | 1,448 | +7 | +0.5% | 69,500 |
| 2025/04/16 | 1,447 | 1,449 | 1,434 | 1,441 | -4 | -0.3% | 69,600 |
| 2025/04/15 | 1,428 | 1,445 | 1,428 | 1,445 | +19 | +1.3% | 57,300 |
| 2025/04/14 | 1,424 | 1,432 | 1,423 | 1,426 | +9 | +0.6% | 62,600 |
| 2025/04/11 | 1,381 | 1,417 | 1,370 | 1,417 | -11 | -0.8% | 133,400 |
| 2025/04/10 | 1,440 | 1,440 | 1,407 | 1,428 | +63 | +4.6% | 110,200 |
| 2025/04/09 | 1,372 | 1,381 | 1,356 | 1,365 | -37 | -2.6% | 171,800 |
| 2025/04/08 | 1,400 | 1,402 | 1,375 | 1,402 | +37 | +2.7% | 143,300 |
| 2025/04/07 | 1,350 | 1,393 | 1,332 | 1,365 | -66 | -4.6% | 235,800 |
| 2025/04/04 | 1,437 | 1,463 | 1,417 | 1,431 | -26 | -1.8% | 261,500 |
| 2025/04/03 | 1,441 | 1,458 | 1,432 | 1,457 | -10 | -0.7% | 142,000 |
| 2025/04/02 | 1,496 | 1,497 | 1,467 | 1,467 | -31 | -2.1% | 141,100 |
| 2025/04/01 | 1,505 | 1,520 | 1,493 | 1,498 | -4 | -0.3% | 100,800 |
| 2025/03/31 | 1,531 | 1,532 | 1,502 | 1,502 | -56 | -3.6% | 162,800 |
| 2025/03/28 | 1,563 | 1,577 | 1,557 | 1,558 | -28 | -1.8% | 89,500 |
| 2025/03/27 | 1,580 | 1,586 | 1,563 | 1,586 | +5 | +0.3% | 114,300 |
| 2025/03/26 | 1,583 | 1,586 | 1,568 | 1,581 | -3 | -0.2% | 111,400 |
| 2025/03/25 | 1,560 | 1,584 | 1,557 | 1,584 | +28 | +1.8% | 167,800 |
| 2025/03/24 | 1,587 | 1,587 | 1,556 | 1,556 | -37 | -2.3% | 172,100 |
| 2025/03/21 | 1,594 | 1,603 | 1,586 | 1,593 | -3 | -0.2% | 114,600 |
| 2025/03/19 | 1,603 | 1,607 | 1,595 | 1,596 | -4 | -0.3% | 66,200 |
| 2025/03/18 | 1,597 | 1,613 | 1,597 | 1,600 | +3 | +0.2% | 103,900 |
| 2025/03/17 | 1,597 | 1,609 | 1,590 | 1,597 | +5 | +0.3% | 106,900 |
| 2025/03/14 | 1,597 | 1,610 | 1,591 | 1,592 | -4 | -0.3% | 105,400 |
| 2025/03/13 | 1,612 | 1,613 | 1,589 | 1,596 | -16 | -1% | 98,000 |
| 2025/03/12 | 1,598 | 1,623 | 1,595 | 1,612 | +12 | +0.8% | 196,000 |
| 2025/03/11 | 1,575 | 1,615 | 1,573 | 1,600 | +24 | +1.5% | 225,700 |
1～
50
件表示中 / 3705件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 146,000円 | -2.4% | -52.3% | 3.90% | 17.47倍 | 0.62倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 213,700円 | +3.1% | -6.5% | 2.25% | 9.92倍 | 1.05倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| 持田薬 | 297,600円 | +5.1% | -7.0% | 2.69% | 19.54倍 | 0.81倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
| 栄研化 | 200,000円 | +4.1% | -3.1% | 2.90% | 17.54倍 | 1.53倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
| ネクセラファーマ | 81,800円 | +20.3% | - | 0.00% | 145.04倍 | 1.08倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム
